ArticleMolecular therapy : the journal of the American Society of Gene Therapy2013
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.Molecular therapy oncolytics · 2023Article
- MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?Cancers · 2022Review
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.Nature communications · 2021Article
- The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?Cellular and molecular life sciences : CMLS · 2021Review
- Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.Cancer immunology research · 2019Article
- Polymer-Based Nanocarriers for Co-Delivery and Combination of Diverse Therapies against Cancers.Nanomaterials (Basel, Switzerland) · 2018Article
- Development and applications of oncolytic Maraba virus vaccines.Oncolytic virotherapy · 2018Review
- Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Cancer immunology research · 2017Article
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.Nature reviews. Clinical oncology · 2017Review
- Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.Neuro-oncology · 2016Article
- Immunogenicity of self tumor associated proteins is enhanced through protein truncation.Molecular therapy oncolytics · 2016Article
- Entropic analysis reveals a connection between the recurrence of cancer and chemotherapy.Saudi journal of biological sciences · 2015Article
- Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.International journal of radiation oncology, biology, physics · 2015Article
- Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression.PloS one · 2015Article
- The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Glioma virus therapies between bench and bedside.Neuro-oncology · 2014Review
- Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.Frontiers in oncology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
Aggressive regrowth of recurrent tumors following treatment-induced dormancy represents a major clinical challenge for treatment of malignant disease. We reported previously that recurrent prostate tumors, which underwent complete macroscopic regression followed by aggressive regrowth, could be cured with a vesicular stomatitis virus (VSV)-expressed cDNA library derived from recurrent tumor cells. By screening the protective, recurrence-derived VSV-cDNA library, here we identify topoisomerase-IIα (TOPO-IIα) as a recurrence-specific tumor antigen against which tolerance can be broken. Tumor recurrences, in two different types of tumor (prostate and melanoma), which had evaded two different frontline treatments (immunotherapy or chemotherapy), significantly overexpressed TOPO-IIα compared with their primary tumor counterparts, which conferred a novel sensitivity to doxorubicin (DOX) chemotherapy upon the recurrent tumors. This was exploited in vivo using combination therapies to cure mice, which would otherwise have relapsed, after suboptimal primary therapy in both models. Our data show that recurrent tumors-across histologies and primary treatments-express distinct antigens compared with the primary tumor which can be identified using the VSV-cDNA library technology. These results suggest that it may be possible to design a few common second-line therapies against a variety of tumor recurrences, in some cases using agents with no obvious activity against the primary tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.